載入中
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.
前收盤價
US$4.95
−US$0.04 · -0.80%
盤中時間採用ET。市場資料可能有所延遲。
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.
日內區間
目前US$4.95
52週區間
目前US$4.95
盤中時間採用ET。市場資料可能有所延遲。
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.
日內區間
目前US$4.95
52週區間
目前US$4.95
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 794.58萬 USD | 355.41萬 USD | 600.22萬 USD | — | — |
| 銷貨成本 | 2.74萬 USD | 1186.57萬 USD | 550.15萬 USD | 441.25萬 USD | — |
| 毛利 | 791.84萬 USD | −831.16萬 USD | 50.07萬 USD | −441.25萬 USD | — |
| 研究與開發 | 1673.45萬 USD | 1189.07萬 USD | 604.47萬 USD | 493.75萬 USD | 254.21萬 USD |
| 銷售、一般及管理費用 | 1144.95萬 USD | 888.58萬 USD | 783.35萬 USD | 484.71萬 USD | 231.2萬 USD |
| 營業費用 | 2818.4萬 USD | 893.81萬 USD | 840.4萬 USD | 539.94萬 USD | 487.03萬 USD |
| 折舊和攤銷 | 2.74萬 USD | 2.74萬 USD | 2.74萬 USD | 2.74萬 USD | 1.61萬 USD |
| 營業利益 | −2026.56萬 USD | −1724.97萬 USD | −790.33萬 USD | −981.19萬 USD | −487.03萬 USD |
| 淨利 | −2122.61萬 USD | −1488.08萬 USD | −798.78萬 USD | −1224.48萬 USD | −489.18萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$12.00
上漲空間 142.42%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI274.11萬0.00%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF105.1萬0.00%954億 USD0.05%US$235+0.80%
Dimensional - US Small Cap ETFDFAS45.94萬0.00%338.69億 USD0.31%US$78.35+0.32%
iShares Micro-Cap ETFIWC31.16萬0.02%13.17億 USD0.60%US$183+0.11%
U.S. Micro Cap Portfolio ETFDFMC19.22萬0.00%75.58億 USD0.43%US$57.813+0.20%
Avantis U.S. Small Cap Equity ETFAVSC5.6萬—30.82億 USD0.25%US$69.98+0.03%
U.S. Vector Equity Portfolio ETF Class SharesDXUV4.14萬0.00%61.81億 USD0.26%US$68.28+0.25%
Dimensional - US Core Equity 2 ETFDFAC2.73萬0.00%885.96億 USD0.21%US$45.33+0.49%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFDimensional - US Small Cap ETFDFASiShares Micro-Cap ETFIWCU.S. Micro Cap Portfolio ETFDFMCAvantis U.S. Small Cap Equity ETFAVSCU.S. Vector Equity Portfolio ETF Class SharesDXUVDimensional - US Core Equity 2 ETFDFACAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
